30
Participants
Start Date
May 31, 2016
Primary Completion Date
September 2, 2020
Study Completion Date
September 2, 2020
Apatinib
Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)
Hebei Medical University Fourth Hospital
OTHER
Peking University First Hospital
OTHER
Peking University Third Hospital
OTHER
Shanxi Province Cancer Hospital
OTHER
Peking University Cancer Hospital & Institute
OTHER